Given that pancreatic cancer exhibits a unique GOT2-dependent glutamine metabolism, there must be other compensatory metabolic pathways for pancreatic cancer cells in vivo to survive under GOT2-deficient conditions. The gene discussed is GOT2; the disease is pancreatic neoplasm.